<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04431375</url>
  </required_header>
  <id_info>
    <org_study_id>ILBS-ACLF-05</org_study_id>
    <nct_id>NCT04431375</nct_id>
  </id_info>
  <brief_title>Efficacy of Addition of Fecal Microbiota Transplant (FMT) and Plasma Exchange to Tenofovir in Comparison to Monotherapy With Tenofovir in ACLF-HBV</brief_title>
  <official_title>Efficacy of Addition of Fecal Microbiota Transplant (FMT) and Plasma Exchange to Tenofovir in Comparison to Monotherapy With Tenofovir in ACLF-HBV</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Liver and Biliary Sciences, India</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Liver and Biliary Sciences, India</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized controlled trial to study the efficacy of addition of FMT &amp; plasma exchange to&#xD;
      tenofovir compared to monotherapy with tenofovir in patients with HBV reactivation who&#xD;
      develops Acute on chronic liver failure.&#xD;
&#xD;
      In this study the patients who meet the inclusion criteria will be randomized to either&#xD;
      receive Tenofovir or with FMT + plasma exchange along with Tenofovir . Blood samples &amp; stool&#xD;
      samples will be taken &amp; analysis will be done accordingly .The patients are followed for 90&#xD;
      days MELD,APACHE &amp; SOFA scores are calculated.Then statistical analysis will be done to find&#xD;
      whether the addition of plasma exchange &amp; FMT adds benefit compared to tenofovir treatment&#xD;
      alone .&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized controlled trial to study the efficacy of addition of FMT &amp; plasma exchange to&#xD;
      tenofovir compared to monotherapy with tenofovir in patients with HBV reactivation who&#xD;
      develops Acute on chronic liver failure.&#xD;
&#xD;
      In this study the patients who meet the inclusion criteria will be randomized to either&#xD;
      receive Tenofovir or with FMT + plasma exchange along with Tenofovir . Blood samples &amp; stool&#xD;
      samples will be taken &amp; analysis will be done accordingly .The patients are followed for 90&#xD;
      days MELD,APACHE &amp; SOFA scores are calculated.Then statistical analysis will be done to find&#xD;
      whether the addition of plasma exchange &amp; FMT adds benefit compared to tenofovir treatment&#xD;
      alone .&#xD;
&#xD;
      Study period: 2 Years&#xD;
&#xD;
      Intervention:&#xD;
&#xD;
      The patients in Group A will receive T.Tenofovir [antiviral] 300mg per oral once a day .&#xD;
&#xD;
      The patients in Group B will receive Plasma exchange 2 sessions alternate day followed by FMT&#xD;
      for 7 days and Tenofovir [antiviral] 300mg PO once a day .&#xD;
&#xD;
      Intravenous antibiotics will be given to all patients included in study empirically, because&#xD;
      of high risk of infection in these patients. Patients with sepsis are excluded from the&#xD;
      study.&#xD;
&#xD;
      Methodology for FMT - Fresh Stool [30 g] is obtained from donor &lt;3 hr before FMT. 150 mL&#xD;
      sterile 0.9N saline is added to sample &amp; homogenized in a blender. It is Continued 3 times in&#xD;
      pulses of 20-30 secs, till homogenous suspension. Slow filtration is done with membrane&#xD;
      filter (330µm) to give adequate time. Filtration is repeated 3 times. Patient is kept NPO for&#xD;
      4 hrs. prior to the instillation .100 ml of fresh filtrate is given for 7 days through&#xD;
      naso-jejunal tube over 5-10 minutes .Patient is kept reclined at 45° for 4 hr. Normal diet is&#xD;
      given after 2 hr of procedure. IV antibiotics are continued as per institutional protocol in&#xD;
      case of sepsis.&#xD;
&#xD;
      Methodology for plasma exchange [PE] - Circulatory access will be established through a&#xD;
      double lumen catheter via the patient's femoral vein. The total exchanged plasma volume will&#xD;
      be 2500-3500 mL, and the Plasma Exchange rate will be 20-25 mL/min. Fresh-frozen plasma (FFP)&#xD;
      will be supplied by the ILBS Blood Bank. Dexamethasone (5 mg) and heparin (2500 U) will be&#xD;
      injected routinely before PE. Heparin will be neutralized at the end of PE by an injection of&#xD;
      20-50 mg protamine sulfate. PE will be repeated alternate day for a total of 2 sessions&#xD;
      Adverse effects: FMT FMT - Sore throat and difficulty in deglutition secondary to&#xD;
      naso-gastric tube insertion Plasma exchange PE&#xD;
&#xD;
        -  Hypocalcemia&#xD;
&#xD;
        -  Hypokalemia&#xD;
&#xD;
        -  Metabolic alkalosis&#xD;
&#xD;
        -  Hypotension&#xD;
&#xD;
        -  Anaphylaxis&#xD;
&#xD;
        -  TRALI TENOFOVIR Tenofovir&#xD;
&#xD;
        -  Reversible proximal renal tubular toxicity.&#xD;
&#xD;
        -  Reduced bone mineral density&#xD;
&#xD;
        -  Manifestations of mitochondrial toxicity (i.e., neuropathy, myopathy, lactic acidosis&#xD;
&#xD;
      Stopping rule of study:&#xD;
&#xD;
        -  Allergic reactions except mild drug reactions&#xD;
&#xD;
        -  Arterial hypotension or development of shock /Hypertension&#xD;
&#xD;
        -  Arrhythmias&#xD;
&#xD;
        -  Development or progression of organ failures during therapy&#xD;
&#xD;
        -  Transfusion related lung injury&#xD;
&#xD;
        -  Uncontrolled Bleeding or DIC&#xD;
&#xD;
        -  Severe dyselectrolytemia( k+&lt;2.5 or &gt;5.5)&#xD;
&#xD;
        -  Seizures/tetany&#xD;
&#xD;
        -  Patients who are undergoing or listed for Transplantation&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 22, 2020</start_date>
  <completion_date type="Anticipated">June 10, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 10, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival in both groups</measure>
    <time_frame>Day 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival in both groups</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in HBV DNA level</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in HBV DNA level</measure>
    <time_frame>60 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in HBV DNA level</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in CTP Score in both groups</measure>
    <time_frame>14 days</time_frame>
    <description>CTP Score ranges from 5 to 15 5=good 15=worst</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in CTP Score in both groups</measure>
    <time_frame>30 days</time_frame>
    <description>CTP Score ranges from 5 to 15 5=good 15=worst</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in CTP Score in both groups</measure>
    <time_frame>60 days</time_frame>
    <description>CTP Score ranges from 5 to 15 5=good 15=worst</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in CTP Score in both groups</measure>
    <time_frame>90 days</time_frame>
    <description>CTP Score ranges from 5 to 15 5=good 15=worst</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in MELD Score in both groups</measure>
    <time_frame>14 days</time_frame>
    <description>MELD Score ranges from 6 to 40 6=good 40=worst</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in MELD Score in both groups</measure>
    <time_frame>30 days</time_frame>
    <description>MELD Score ranges from 6 to 40 6=good 40=worst</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in MELD Score in both groups</measure>
    <time_frame>60 days</time_frame>
    <description>MELD Score ranges from 6 to 40 6=good 40=worst</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in MELD Score in both groups</measure>
    <time_frame>90 days</time_frame>
    <description>MELD Score ranges from 6 to 40 6=good 40=worst</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patient's with improvement in hepatic failure calculated by MELD Na and CTP scores.</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patient's with improvement in hepatic failure calculated by MELD Na</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patient's with improvement in hepatic failure calculated by CTP scores.</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patient's with improvement in hepatic failure calculated by MELD Na</measure>
    <time_frame>60 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patient's with improvement in hepatic failure calculated by CTP scores.</measure>
    <time_frame>60 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patient's with improvement in hepatic failure calculated by MELD Na.</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patient's with improvement in hepatic failure calculated by CTP scores.</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in microbiota profile in both groups</measure>
    <time_frame>10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in microbiota profile in both groups</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in microbiota profile in both groups</measure>
    <time_frame>60 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in microbiota profile in both groups</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma cytokine profile in both groups</measure>
    <time_frame>10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma cytokine profile in both groups</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma cytokine profile in both groups</measure>
    <time_frame>60 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse Events in both groups</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Acute-On-Chronic Liver Failure</condition>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>plasma Exchange+Tenofovir+FMT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive Plasma exchange 2 sessions alternate day followed by FMT for 7 days and Tenofovir [antiviral] 300mg PO once a day .</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tenofovir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TabletTenofovir [antiviral] 300mg per oral once a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Plasma Exchange</intervention_name>
    <description>Plasma exchange 2 sessions alternate day followed by FMT for 7 days and Tenofovir [antiviral] 300mg PO once a day .</description>
    <arm_group_label>plasma Exchange+Tenofovir+FMT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir</intervention_name>
    <description>Tenofovir [antiviral] 300mg PO once a day .</description>
    <arm_group_label>Tenofovir</arm_group_label>
    <arm_group_label>plasma Exchange+Tenofovir+FMT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fecal Mircobiota Transplantation</intervention_name>
    <description>FMT for 7 days</description>
    <arm_group_label>plasma Exchange+Tenofovir+FMT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age - 18-75 years&#xD;
&#xD;
          -  Patients with ACLF - HBV reactivation according to APASL guidelines.&#xD;
&#xD;
          -  MELD &lt; 30 WITH AKI,HE&#xD;
&#xD;
          -  MELD &lt; 30 WITH OUT EXTRAHEPATIC FAILURE&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  MELD &gt; 30&#xD;
&#xD;
          -  Co existing hepatitis A,E,D&#xD;
&#xD;
          -  HCC&#xD;
&#xD;
          -  Sepsis&#xD;
&#xD;
          -  Alcohol intake, substance abuse, HIV, IBD, chronic constipation or diarrhoea&#xD;
&#xD;
          -  Allergy to plasma, protamine or heparin,&#xD;
&#xD;
          -  Active hemorrhage or disseminated intravascular coagulation (DIC)&#xD;
&#xD;
          -  Unstable hemodynamics (e.g., blood pressure &lt;90/60 mmHg, heart rate &gt;100 bpm),&#xD;
&#xD;
          -  Cerebral or myocardiac infarction&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dr G. Srinivasa Reddy, MD</last_name>
    <phone>01146300000</phone>
    <email>srinivasareddygolamari@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institute of Liver &amp; Biliary Sciences</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110070</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr G Srinivasa Reddy, MD</last_name>
      <phone>01146300000</phone>
      <email>srinivasareddygolamari@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 4, 2020</study_first_submitted>
  <study_first_submitted_qc>June 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 16, 2020</study_first_posted>
  <last_update_submitted>August 3, 2020</last_update_submitted>
  <last_update_submitted_qc>August 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Liver Failure</mesh_term>
    <mesh_term>End Stage Liver Disease</mesh_term>
    <mesh_term>Acute-On-Chronic Liver Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

